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are not a homogenous entity and can be further subclas-
sified into biologically relevant subgroups. A separation 
based on the proliferative index (Ki-67 >55%) was shown 
to have clinical implications regarding response to che-
motherapy and prognosis: NEC with Ki-67 >55% re-
sponded better to platinum-based chemotherapy and, 
nevertheless, had a 4 months’ shorter median survival 
than G3 NEN in the lower proliferative range (20–55%) 
 [1] . More recent publications show that morphological 
differentiation and Ki-67 are able to separate prognostic 
groups among G3 cases, and therefore a separation of 
well-differentiated G3 NET from poorly differentiated 
G3 NEC is emerging  [2–4] . The exact criteria need to be 
defined both on the morphological and on the molecular 
level. The spectrum of mutations of well-differentiated 
 Introduction 
 Neuroendocrine carcinomas (NEC) are rare in the 
gastrointestinal (GI) tract, whereas they are frequent in 
the form of small cell carcinoma (SCLC) in the lung. 
Therefore, most of the suggested guidelines arise from 
analogy to SCLC. As for other extrapulmonary primary 
tumor locations, published data on NEC of the GI tract 
are scarce. This guideline encompasses all WHO grade 3 
(G3) gastroenteropancreatic (GEP) neoplasms; however, 
in the future, G3 neuroendocrine neoplasms (NEN) will 
probably be separated according to differentiation, as ex-
plained below, and potentially according to organ of ori-
gin, such as for well-differentiated neuroendocrine tu-
mors (NET) G1/G2.
 According to the WHO classification of 2010, NEC are 
defined as poorly differentiated NEN with Ki-67 >20% 
and hence G3. Increasing evidence suggests that G3 NEN 
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pancreatic NET is different from that of pancreatic NEC 
 [5] , suggesting different ways of tumorigenesis. However, 
to date there are no solid data that adequately address the 
implications of these observations in terms of treatment 
effect of the different available regimens. 
 Epidemiology 
 The GEP tract is the most common site of extrapulmo-
nary NEC, accounting for 35–55% of all NEC originating 
from the lung. Only about 5% of all GI NEN have Ki-67 
>20%  [6, 7] . This frequency might differ by organ, with 
about 7% in the pancreas  [7] and up to 40% in the colon 
 [8] . GEP NEC are therefore very rare neoplasms repre-
senting <1% of all GI malignancies. Up to 85% have me-
tastases at the time of diagnosis (65% distant)  [1, 6] . Me-
tastases are most frequently found in the liver (70%) fol-
lowed by the lung (15%), bone (15%) and brain (4%)  [1] . 
No gender difference has been identified. The mean age 
at diagnosis is 60 years  [1] .
 Clinicopathological Features 
 As the great majority of these tumors are not associ-
ated with a hormonal syndrome (<5%), and more than 
two thirds of all patients present with advanced disease, 
clinical presentation is dominated by tumor-derived site-
specific symptoms and the constitutional syndrome char-
acteristics of advanced cancer (anorexia, weight loss and 
fatigue). Depending upon tumor location, a wide variety 
of symptoms may occur. The neuroendocrine nature of 
these tumors is generally not suspected from the clinical 
presentation, although as in SCLC paraneoplastic syn-
dromes may occur in some patients (i.e., Cushing or In-
appropriate ADH Secretion Syndromes). A detailed an-
amnesis and physical examination are fundamental to ap-
propriately guide diagnostic procedures.
 According to the WHO 2010 classification, NEC are 
poorly differentiated highly aggressive neoplasms, some-
times with organoid features, marked nuclear atypia and 
multifocal necrosis  [9] . A diffuse expression of neuroen-
docrine markers (diffuse for synaptophysin, focal for 
chromogranin A, and the latter may be absent) separates 
the entity pathologically from poorly differentiated carci-
noma. 
 The grading introduced by ENETS in 2006  [10] of 
NEC is by definition G3, either based on a proliferation 
index >20% or >20 mitoses in 10/HPF. This proposition 
has been adopted by the WHO classification and was 
shown repeatedly to be clinically applicable in predicting 
a very aggressive subset of NEN  [7] .  
 Prognosis and Survival 
 Survival is poor in NEC, ranging from 38 months for 
patients with localized disease to 5 months in the meta-
static setting according to the SEER population registry 
data, which involved 2,546 patients diagnosed with GI 
NEC from 1973 to 2012 in the USA  [11] . Median surviv-
al in the metastatic setting may be as short as 1 month for 
patients receiving only best supportive care, up to 12–19 
months for those treated with best available therapy  [1, 
12] . Only 5% of all patients are long-time survivors  [7] . 
Progression-free survival after cisplatin-based chemo-
therapy and overall survival differs according to the loca-
tion of the primary tumor, with poorer reported out-
comes in esophageal, colonic and rectal NEC compared 
to gastric and pancreatic ones in some large European 
series  [1] . In contrast, survival of pancreatic NEC was 
poorer in Japanese patients  [13] . A poor performance sta-
tus, high proliferation rate, elevated baseline lactate dehy-
drogenase (LDH) and thrombocytosis are other factors 
that have also been associated with a worse prognosis.
 Diagnostic Procedures  
 Biochemical Tests 
 Plasma chromogranin A may be elevated in up to two 
thirds of patients with advanced NEC  [1] , although the 
levels are generally lower than those observed in well-dif-
ferentiated tumors  [14, 15] . In contrast, the levels of oth-
er tumor markers such as neuron-specific enolase (NSE) 
are higher in poorly differentiated tumors than in NET, 
and they are significantly associated with survival. How-
ever, the role of circulating tumor markers to predict and 
monitor outcome has not been properly assessed in ex-
trapulmonary NEC. Screening for other hormonal mark-
ers is not justified unless clinically indicated.
 Endoscopic and Imaging Procedures  
 Endoscopic examination of the primary tumor site is 
recommended, which is also useful to obtain a biopsy for 
histological diagnosis. If this is not feasible, endoscopic 
ultrasound-guided or percutaneous procedures can be 
useful. Once the histological diagnosis of a G3 NEC has 
been confirmed, complete staging using whole-body CT 
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scan or MRI should be performed to assess the extent of 
disease and to design the most appropriate therapeutic 
strategy. A lung primary should be reasonably excluded 
(negative imaging studies of the lung). FDG-PET may be 
useful if radical surgery is being pursued or if clarification 
of equivocal findings on conventional imaging may 
change the therapeutic approach. Radiolabeled soma-
tostatin analogue scans are not routinely recommended, 
as poorly differentiated tumors generally do not express 
somatostatin receptors. However, data from large series 
indicate positive SRI findings in a substantial proportion 
of patients with certain primary tumors (up to 45% of 
pancreatic NEC), particularly those with proliferative in-
dexes in the low range of G3, and may differ by histolog-
ical subtype (45% of small cell vs. 32% of large cell NEC) 
 [1] . In the absence of neurological symptoms, brain CT 
or MRI are not recommended, as the incidence of brain 
metastasis in extrapulmonary NEC is rather low (<5%) 
 [1] . Bone scans are neither indicated if there is no clinical 
or biochemical suspicion of bone metastasis. In the pres-
ence of elevated LDH, peripheral blood leukoerythro-
blastosis or thrombocytopenia, a bone marrow biopsy 
may be considered. 
 Minimal Consensus Statement 
 Clinical signs and symptoms should guide the appropriate 
diagnostic procedures (summarized in fig. 1). Chromogranin A 
and NSE testing is not mandatory, although they may be useful 
if elevated at diagnosis. A proper assessment of their utility in 
extrapulmonary NEC is, however, pending. Other hormone tests 
are not routinely recommended. 
 A minimal diagnostic workup should include site-specific
endoscopic assessment with tumor biopsy, and whole-body CT 
scan (and/or MRI) for tumor staging. In patients with metastatic 
disease, an ultrasound-guided percutaneous biopsy may be per-
formed if feasible. Somatostatin receptor scintigraphy is not rou-
tinely indicated but may be considered in tumors with prolifera-
tive indexes in the low range of G3 (Ki-67 <55%). Bone scans or 
brain imaging (CT or MRI) should not be performed in the ab-
sence of site-specific symptoms. FDG-PET may be considered in 
patients in whom radical surgery is being pursued or if clarifica-
tion of equivocal findings on conventional imaging may change 
the therapeutic approach. FDG-PET may be useful in resectable 
cases for whole body assessment.
 Histopathology and Genetics of Poorly 
Differentiated NEC 
 Histopathologically, NEC show a neuroendocrine 
phenotype by immunohistochemistry, in large cell NEC 
a positivity for synaptophysin is mandatory, chromo-
granin A staining is variable and may be weak or absent. 
Rarely, both markers may be negative in small cell NEC 
(<5%  [1] ). Other neuroendocrine markers such as NSE or 
CD56 are less specific and must be used with caution. Ki-
67 is by definition >20%  [10] and in half of the cases, it is 
>55%  [1] . Punctate or geographic necrosis is frequent. 
Reporting of the immunohistochemical results above as 
well as the proliferative index by mitosis is essential. So-
matostatin receptor 2A (Sstr 2a) immunohistochemistry 
is optional  [16, 17] . Over 90% of G3 NEC do not produce 
hormones  [17] .
 In the setting of a carcinoma of unknown primary, the 
expression of transcription factors such as Ttf1, Cdx-1 or 
Isl1 cannot be used to help localize the site of the primary 
tumor  [18] .
 Care must be taken to differentiate NEC from poorly 
differentiated adenocarcinoma, especially in certain or-
gans such as the pancreas, where a differential diagnosis 
with acinic cell carcinoma may be particularly challeng-
ing  [19] . NEC are separated into large cell and small cell 
types; however, no clear clinicopathological differences 
between the two types have been shown for the pancreas 
 [19] . 
 Pancreatic NEC show a genetic profile different from 
NET with frequent mutations in p53 and RB  [5] and a 
much higher mutation rate (in review), similar to pulmo-
nary small cell carcinoma. Furthermore, up to 40% of all 
NEC present a minor component of adenocarcinoma 
(colon  [20] , stomach  [21] ) or squamous cell carcinoma 
(esophagus, anus). If the non-endocrine component ex-
ceeds 30%, the neoplasm is classified as mixed adenoneu-
roendocrine carcinoma. Differentiation together with 
proliferation and mutation spectrum will be important in 
discriminating G3 NET from G3 NEC in the future  [2–4] .
 Minimal Consensus Statement 
 A routine pathological report should include morphology 
(large cell vs. small cell and differentiation), staining for chromo-
granin A and synaptophysin and Ki-67 estimate or/and mitotic 
count. 
 Treatment 
 Evidence to support treatment recommendations for 
GEP G3 NEC is scarce and derives from limited retro-
spective series and very few small non-controlled clini-
cal trials. Most investigators, therefore, treat this entity 
in analogy to the much more common SCLC due to 
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their histological and clinical resemblance. Bearing 
these caveats in mind, guidance is hereby provided 
(fig. 2). Nevertheless, generating prospective and pref-
erably controlled data is greatly needed and encouraged 
in this setting.
 Surgery 
 Curative surgery is usually attempted in localized dis-
ease, although retrospective series indicate that it is rare-
ly curative as a sole therapeutic modality  [22] . Given the 
high relapse rate observed following radical surgery, most 
clinicians would advocate platinum-based adjuvant ther-
apy in this setting. Data reported by Casas et al. of a large 
series of esophageal small cell carcinomas support this 
approach  [23] . In this study, survival was 20 months for 
patients who received systemic chemotherapy in addition 
to local treatment versus only 5 months for those who 
were treated with local therapy only, and the type of treat-
ment was found to be an independent prognostic factor 
in multivariate analysis. Some authors propose neoadju-
vant chemotherapy followed by definitive surgery, al-
though data to support this approach are scarce  [24] . In 
patients with important comorbidities or where the tu-
mor’s anatomical site makes surgical resection not advis-
able due to high morbidity (i.e., esophagus), a definitive 
course of radiotherapy and chemotherapy is a reasonable 
treatment strategy. 
 In the context of advanced metastatic disease, debulk-
ing or cytoreductive surgery and surgical resection of me-
tastasis are not recommended. Other ablative strategies of 
liver metastasis (i.e., radiofrequency ablation, TACE) are 
also discouraged. 
 Medical Therapy 
 Chemotherapy is an essential part of the multimodal-
ity approach for localized NEC and the mainstay of care 
in advanced disease. Survival of patients with metastatic 
NEC treated with chemotherapy varies widely (from 7 to 
19 months) but shows a substantial improvement over 
that reported for patients that receive only best support-
ive care (1 month). No randomized studies, however, 
have properly addressed the magnitude of this effect so 
far. Swift referral for consideration of palliative chemo-
therapy is recommended as performance status deterio-
ration may occur rapidly and preclude further therapy. 
Based on their established role in metastatic SCLC, cis-
platin and etoposide (EP) have been one of the most 
widely used regimens in GEP NEC ( table 1 )  [1, 13, 25–
29] , with response rates in the largest most recent series 
of  ∼ 30% and median survival of around one year. In one 
of the largest series published to date, Sørbye et al.  [1] ob-
served that Ki-67 was significantly associated with re-
sponse to chemotherapy. Indeed, patients with Ki-67 val-
ues >55% had a greater response rate (42 vs. 15%) al-
Recommended
- CT or MRI
 (chest/abdomen/pelvis)
Only if clinically indicated
- FDG-PET – if surgery is
 being considered
- Additional according to
 symptoms
Initial diagnosis
NEC and G3 NET
 Liver and kidney function
 Other biochemical 
 markers if clinically
 indicated
 Synaptophysin,
 chromogranin A
 Ki-67
 SSTR 2a (optional)
Resected disease
- Contrast CT scan every 
 3–6 months for 2–3 years, 
 and then every 6–12 
 months
Advanced disease
- Contrast CT scan every 
 2–3 months if on therapy
Follow-up
 Biomarkers if elevated at
 diagnosis
 Other tests only if 
 clinically indicated
Imaging
Laboratory
Pathology
 Fig. 1. Diagnostic algorithm for NEC and 
G3 NET.  
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though poorer survival (10 vs. 14 months) than patients 
with Ki-67 values <55%. Other negative prognostic fac-
tors in this study were a poor performance status, prima-
ry colorectal tumors and elevated platelets or LDH levels, 
which were all associated with decreased survival. 
 Alternative regimens substituting carboplatin for cis-
platin, or irinotecan for EP, have been validated in SCLC 
and seem at least equivalent in terms of efficacy in lim-
ited series of GEP NEC ( table 1 )  [13, 30–35] , with differ-
ent toxicity profiles. In the context of advanced stage 
SCLC, a randomized study conducted in Japan demon-
strated that the combination of irinotecan and cisplatin 
(IP) was associated with improved overall survival as 
compared to the standard cisplatin and EP combination 
 [36] . Two subsequent randomized Western trials, how-
ever, failed to confirm this superiority. Both regimens 
produced comparable efficacy, with less hematological 
and greater GI toxicity with the IP combination (particu-
larly diarrhea and vomiting)  [37, 38] . Consistent with 
these findings, large retrospective data of systemic che-
motherapy for advanced GEP NEC from 23 Japanese in-
stitutions documented that the IP regimen was associ-
ated with greater response rates (50 vs. 28%) and sur vival 
(13 vs. 7 months) than the EP regimen, and this differ-
ence was more remarkable in hepatobiliopancreatic 
NEC. Prognostic factors in this study included primary 
tumor site (those with hepatobiliopancreatic primaries 
having the worst prognosis) and elevated baseline LDH 
levels, whereas treatment schedule was not an indepen-
dent predictive factor for survival. Three-drug regimens 
such as cisplatin, EP and paclitaxel do not seem to sub-
stantially improve efficacy and are significantly more 
toxic  [39] . 
 Evidence for salvage therapy in patients progressing 
on first-line platinum-based regimens is very limited 
( table 1 )  [1, 13, 40–45] . Overall, response rates are lower 
(18% in the NORDIC NEC study), although small series 
have documented response rates of 23–40% with oxali-
platin-based (XELOX, FOLFOX) or irinotecan-based 
(FOLFIRI, IP) regimens. Welin et al. reported a 33% re-
sponse rate with temozolomide, alone or in combina-
tion with capecitabine and bevacizumab, in a cohort of 
25 patients with poorly differentiated NEC (17 of GEP 
origin)  [44] . A Ki-67 index <60% was predictive for re-
sponse to treatment and survival. In contrast, no re-
sponses were observed in another series of 28 NEC cas-
es treated with temozolomide monotherapy  [45] . Re-
treatment with platinum/EP may also be considered in 
patients that achieve good durable responses upfront 
and progress after a treatment break of at least 3 months, 
provided no cumulative toxicity (i.e., neurotoxicity, oto-
toxicity) precludes further treatment with platinum 
 Chemotherapy
 Radiotherapy may be considered in 
 selected sites (bone, brain, ...) for 
 symptom control
Special considerations for well-differentiated G3
ض Platinum-based regimens seem to be less
 active than in poorly differentiated tumors
ضOther regimens may be considered (i.e.
 TMZ-based)
ض PRRT may be considered in SSTR-positive
 tumors
 Chemotherapy; radiotherapy
 ض Cisplatin or carboplatin and etoposide are generally recommended in the adjuvant setting or as
  first-line therapy in advanced disease. Alternative regimens substituting irinotecan for etoposide
  may also be employed as first-line therapy in advanced disease.
 ض Irinotecan or oxaliplatin-based regimens may be considered as second-line therapy.
 Clinical judgement should be used.
 
Distant metastases
Radical surgery
+ adjuvant 
chemotherapy 
± radiotherapy
Resectable
Locoregional 
radiotherapy
+ chemotherapy
Locoregional unresectable
NEC and G3 NET
 Fig. 2. Therapeutic algorithm for NEC and G3 NET. 
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agents. Other agents tested include amrubicin, S-1 or 
taxanes ( table 1 ).
 Other Treatment Options (Radiotherapy, PRRT) 
 In contrast to recommendations for patients with 
limited-stage SCLC, prophylactic cranial irradiation is 
not indicated in patients with successfully treated local-
ized GEP NEC, as the incidence of brain metastasis in 
patients with extrapulmonary NEC is rather low. Pallia-
tive radiotherapy may be considered for localized bone 
metastasis to control pain or to prevent skeletal compli-
cations. 
 Although a subgroup of NEC expresses somatostatin 
receptors, there are no data to support the use of soma-
tostatin analogs in this context. Some case reports have 
communicated long-lasting responses to peptide recep-
tor radionucleotide therapy (PRRT) in NEC with high 
expression of somatostatin receptors, but this therapeutic 
strategy is generally not successful in the majority of G3 
tumors  [46] . 
 Table 1.  Series of patients with advanced G3 NEC of the GI tract treated with chemotherapy
First author Patients, 
n
Primary site Chemotherapy regimen RR, 
%
Survival, 
months
First-line therapy
Moertel [25] 18 GEP (14), lung (1), UKP (3) Cisplatin/EP 67 19 
Mitry [26] 41 GEP (20), lung (10), H&N (4), UKP (7) Cisplatin/EP 42 15 
Deutschbein [28] 18 G3 NEC (primary NR) Cisplatin/EP +/– paclitaxel 17 NR
Iwasa [27] 21 Hepatobiliar and pancreas Cisplatin/EP 14 6 
Patta [29] 8 Colorectal Cisplatin/EP 63 10 
Sørbye [1] 252 GEP (69%), UKP (31%)
129 Cisplatin/EP 31 12 
67 Carboplatin/EP 30 11 
Hainsworth [39] 78 GEP (15), lung (7), skin (4), other (4), UKP (48) Paclitaxel/carboplatin/EP 53 15 
Ramella [30] 27 GEP (18), H&N (1), GU (1), UKP (7) Platinum/irinotecan 46 12 
Okita [31] 12 Gastric IP 75 23 
Nakano [32] 35 GEP (9), H&N (18), GU/GYN (5), UKP (12) IP 64 NR
Okuma [33] 12 Esophagus IP 50 13 
Lu [34] 16 GEP IP 57 11 
Kulke [35] 4 GEP/UKP IP 25 NR
Yamaguchi [13] 258 GEP NEC/MANEC
160 IP 50 13 
46 Cisplatin/EP 28 7 
Second- or third-line therapy
Hentic [40] 19 GEP FOLFIRI 31 18 
Welin [44] 25 GEP (17), UKP (5), lung (3) Temozolomide +/– capecitabine 
+/– bevacizumab
33 22 
Olsen [45] 28 GEP (18), UKP (6), lung (1), GU (3) Temozolomide 0 4 
Bajetta [41] 13 GEP (58%) XELOX 23 NR
Ferrarotto [42] 9 GEP (75%) XELOX 29 NR
Hadoux [43] 20 G3 NEC (primary NR) FOLFOX 29 10 
Yamaguchi [13] 25 GEP NEC/MANEC Amrubicin 4 8 
23 GEP NEC/MANEC Platinum/EP 17 5 
21 GEP NEC/MANEC Irinotecan 5 6 
11 GEP NEC/MANEC S-1 27 12 
5 GEP NEC/MANEC IP 40 9 
Sørbye [1] 100 GEP, UKP Various (Taxane-22; Tmz-35) 18 19 
 GU = Genitourinary; GYN = gynecological; H&N = head and neck; MANEC = mixed adenoneuroendocrine carcinoma; NR = not 
reported; RR = response rate; UKP = unknown primary.
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 Minimal Consensus Statement on Treatment 
 For patients with localized disease, a combination of plati-
num-based chemotherapy with local treatment consisting of sur-
gery, radiotherapy or both probably offers the greatest likelihood 
of long-term survival. Debulking or surgical resection of metas-
tasis is not recommended. Systemic chemotherapy is indicated in 
advanced inoperable disease, provided the patient has adequate 
organ function and performance status, otherwise the patient 
should be rapidly referred for consideration of palliative chemo-
therapy. The combination of cisplatin and EP, or alternative reg-
imens substituting carboplatin for cisplatin or irinotecan for EP, 
are recommended as first-line therapy. Since response rates of 
these regimens are lower in patients with a Ki-67 value in the 
lower range of G3 (20–55%), other treatment options may be ex-
plored in these patients (especially for NEC of GI origin). While 
second-line regimens have not been evaluated rigorously, op-
tions include temozolomide-, irinotecan- or oxaliplatin-based 
schedules as main alternatives. There are no data to support the 
use of somatostatin analogs or PRRT in patients with GEP NEC 
expressing somatostatin receptors. Prophylactic cranial irradia-
tion is not indicated in patients with limited-stage disease in 
complete remission.
 Follow-Up 
 Follow-up recommendations are based on expert opin-
ion as there is no solid evidence to support the type and 
frequency of performance of specific procedures. Patients 
with localized G3 NEC who have undergone complete re-
section are recommended to be followed every 3–6 months 
during the first 2–3 years following surgery, and then ev-
ery 6–12 months up to 5 years. Conventional imaging (CT 
scan or MRI) should be performed during these follow-up 
visits, but testing for general tumor markers (i.e., chromo-
granin A or NSE) is only indicated if elevated at diagnosis. 
Somatostatin receptor imaging procedures are generally 
not warranted in this setting, particularly if negative at di-
agnosis. FDG-PET may be indicated if equivocal findings 
are encountered on conventional imaging and/or if sal-
vage surgery is being considered. 
 Follow-up of patients with advanced disease should be 
customized depending upon tumor kinetics (the Ki-67 
proliferative index and the actual growth rate document-
ed by serial CT scans), treatment strategy, side effects of 
therapy and general health condition. Clinical assessment 
visits should be scheduled frequently, as these patients 
generally present fast tumor kinetics, are highly symp-
tomatic and/or receive toxic agents. Clinical judgement is 
advised to establish the appropriate assessment interval. 
Conventional imaging procedures are recommended to 
be performed every 2–3 months while on active therapy.
 Minimal Consensus Statement 
 In patients with localized R0/R1 resected G3 NEC, conven-
tional imaging (CT and/or MRI) and assessment of circulating 
tumor markers (if elevated at baseline) are recommended to be 
performed every 3 months during the first 2–3 years after surgical 
resection, and every 6–12 months up to 5 years following surgery. 
In patients with advanced disease G3 NEC, frequent clinical as-
sessment visits should be performed, and conventional imaging 
is recommended every 2–3 months while on active therapy.
 Please also refer to consensus guideline updates for 
other GEP NET [ 47–52 , this issue].
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